Saturday, October 17, 2026 from 1:45 p.m. to 3:15 p.m. MDT at Salt Palace Convention Center - Ballroom J
Available for 1.50 hours of CPE creditActivity Number: 0217-0000-26-161-L01-PActivity Type: A Knowledge-Based ActivityThis session will explore the evolving role of advanced therapies in the management of multiple sclerosis (MS), integrating foundational disease knowledge with emerging cellular therapy applications. Attendees will gain a comprehensive understanding of MS pathophysiology, current treatment approaches, unmet clinical needs, and patient considerations that inform therapeutic decision-making. The session will also highlight the growing role of hematopoietic stem cell transplantation (HSCT) and cellular therapy in MS, including evidence for its use, safety considerations, and practical aspects of incorporating HSCT into care. Through evidence-based discussion and real-world insights, participants will leave with a deeper understanding of the modern MS treatment landscape and the pharmacist’s role in optimizing outcomes for patients pursuing advanced therapeutic options.
Learning Objectives1. Describe the evolving treatment landscape of multiple sclerosis, including unmet needs that inform consideration of advanced therapies such as HSCT and cellular therapy.
2. Summarize key guideline recommendations and pivotal literature supporting the use of autologous HSCT in relapsing multiple sclerosis and ongoing trials investigating cellular therapy.
3. Review the evidence for the efficacy and safety of HSCT compared to high-efficacy disease-modifying therapies (DMTs) in highly active relapsing-remitting MS.
4. Identify appropriate patient selection criteria and risk-benefit considerations for HSCT and cellular therapy in MS.
5. Recognize acute and long-term toxicities associated with HSCT, including supportive care needs and monitoring parameters.
 | | Moderator: | Julia Fadul, Pharm.D. |
|
From DMTs to HSCT: Understanding the Evolving MS Treatment Paradigm1:45 p.m. to 2:30 p.m. | | Speaker: | Erin L. Thompson, Pharm.D., B.S.Pharm, BSEd, BCACP, BCPS | | Clinical Pharmacist
The Toledo Clinic, Toledo, OH |
|
|
Optimizing HSCT and Cellular Therapy in MS: Patient Selection, Monitoring, and Adverse Event Management2:30 p.m. to 3:15 p.m. | | Speaker: | Elizabeth Eubanks, Pharm.D., MPH, BCOP |
|
|